Key result
Nebivolol is associated with ~41% lower MACE but similar mortality versus bisoprolol in reduced-LVEF STEMI.
Why the study?
The long-term clinical outcomes comparing nebivolol and bisoprolol in STEMI patients with reduced LVEF who underwent successful PCI with DES were not established.
Does nebivolol reduce all-cause death or MACE in STEMI patients with reduced LVEF treated with DES compared to bisoprolol?
Cohort (n=1,317)
Yes
Does nebivolol reduce all-cause death or MACE in STEMI patients with reduced LVEF treated with DES compared to bisoprolol?
Hazard Ratio: 0.762 (95% CI 0.486–1.193)
Absolute Event Rate: 5.5% vs 7.1%
p-value: p=0.257
In STEMI patients with reduced LVEF undergoing PCI with DES, nebivolol at discharge was associated with a lower risk of MACE compared to bisoprolol, though all-cause mortality was similar.
No takes yet. Share an insight, caveat, or question.
Nebivolol was associated with lower MACE but similar mortality versus bisoprolol; hypothesis-generating, prospective trials needed before changing practice.
Kim et al. (2026) conducted a cohort in STEMI with reduced LVEF (n=1,317). Nebivolol vs. Bisoprolol was evaluated on all-cause death (HR 0.762, 95% CI 0.486-1.193, p=0.257). Nebivolol prescription at discharge in STEMI patients with reduced LVEF was associated with similar 3-year all-cause death (HR 0.762; P=0.257) but lower MACE (HR 0.586; P=0.002) versus bisoprolol.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: